In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report).

Saliva-based diagnostics have emerged as a transformative approach in medical testing, offering a non-invasive and efficient ...

From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase conference in San Francisco and the Global Biopharma ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an ...

Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that Pankaj Mohan, Ph.D., Chief ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

The "Home Care Testing Market Size, Share & Trends Analysis Report By Age, By Sample, By Test Type, By Distribution Channel, ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

“Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the ...

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context ...